title: Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.
abstract: The Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q) is a psychometric measure of patient satisfaction with bisphosphonate treatment for osteoporosis. The study was a multicenter, nationwide, cross-sectional, patient-reported outcome study conducted to evaluate treatment satisfaction and quality of life using the OPSAT-Q in patients receiving oral bisphosphonate therapy. This study enrolled postmenopausal women from 43 hospitals and 112 clinics who had intermittently taken oral bisphosphonates for treatment of osteoporosis. 4,220 postmenopausal Korean women with a mean age of 65.3 years and a mean body mass index of 22.9 kg/m(2) participated in the study. All items within each subscale domain were more highly correlated with their hypothesized subscale domain relative to the other subscale domains, and all 16 items were significantly correlated with an overall composite satisfaction score (CSS). All scores showed acceptable internal consistency reliability (Cronbach's alpha >0.70, range 0.88-0.91). Comparisons of OPSAT-Q scores were made between selective subgroups of participants: monthly versus weekly administration, years of taking bisphosphonates, smoking habitus, acid-related medication and comorbid conditions. Mean OPSAT-Q subscale domains and CSS were higher for users of monthly bisphosphonates, with shorter duration, non-smokers, and non-users of acid-related medication. Mean OPSAT-Q subscale domain scores of side-effects were high for absence of comorbid conditions. The OPSAT-Q demonstrated acceptable measurement properties, including validity and reliability of subscale domains and CSS, in oriental women with postmenopausal osteoporosis. Postmenopausal women intermittently using oral bisphosphonate therapy reported increased satisfaction with monthly administration, with shorter duration, non-smokers, non-users of acid-related medication, and an absence of comorbid conditions.
authors.affiliation: Department of Endocrinology and Metabolism, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Ki Won
authors.initials: KW
authors.lastname: Oh
authors.forename: Deog-Yoon
authors.initials: DY
authors.lastname: Kim
authors.forename: Yil-Seob
authors.initials: YS
authors.lastname: Lee
authors.forename: Moo Il
authors.initials: MI
authors.lastname: Kang
mesh_terms: D000284:Administration, Oral; D000368:Aged; D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D003710:Demography; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005843:Geography; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D017060:Patient Satisfaction; D015203:Reproducibility of Results; D056910:Republic of Korea; D011795:Surveys and Questionnaires
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references.citation: Health Qual Life Outcomes. 2006 Jul 11;4:42
references.pmid: 16834773
references.citation: QJM. 2009 Jan;102(1):35-42
references.pmid: 18842684
references.citation: Osteoporos Int. 2006;17(11):1638-44
references.pmid: 16896510
references.citation: Osteoporos Int. 2007 Aug;18(8):1023-31
references.pmid: 17308956
references.citation: Nihon Rinsho. 2009 Jan;67(1):206-12
references.pmid: 19177774
references.citation: Calcif Tissue Int. 2009 Nov;85(5):389-97
references.pmid: 19816648
references.citation: Osteoporos Int. 2008 Oct;19(10):1421-9
references.pmid: 18351427
references.citation: Bone. 2011 Jun 1;48(6):1298-304
references.pmid: 21421092
references.citation: Joint Bone Spine. 2008 May;75(3):303-10
references.pmid: 18069036
references.citation: Osteoporos Int. 2009 Sep;20(9):1583-94
references.pmid: 19153677
references.citation: Osteoporos Int. 2011 Oct;22(10):2735-42
references.pmid: 21104227
references.citation: South Med J. 2009 May;102(5):486-92
references.pmid: 19373149
references.citation: Mayo Clin Proc. 2006 Aug;81(8):1013-22
references.pmid: 16901023
references.citation: Mayo Clin Proc. 2005 Jul;80(7):856-61
references.pmid: 16007889
references.citation: Curr Med Res Opin. 2005 Dec;21(12):1895-903
references.pmid: 16368038
references.citation: J Bone Miner Res. 2008 Oct;23(10):1569-75
references.pmid: 18505366
references.citation: J Womens Health (Larchmt). 2009 Jul;18(7):935-43
references.pmid: 19563245